Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>According to the government, over 30 vaccine candidates are being developed in India. </li><li>Serum Institute of India has entered phase II/III trials and is leading the vaccine development race in the country. </li><li>Whereas, both Bharat Biotech and Zydus Cadila are conducting <a href="https://health.economictimes.indiatimes.com/news/industry/human-clinical-trials-for-covid-19-vaccine-initiated-in-india-icmr/76969682">phase I/II human</a> trials right now. </li></ul>As India records over 1 million COVID-19 deaths, scientists in India are racing against time to develop an effective vaccine. There are 191 COVID-19 vaccine developments in the works around the world right now, and 41 of them are under clinical evaluation, according to the World Health Organisation. According to the Indian government, over 30 vaccine candidates are being developed in India. Three of them are in the advanced stages of the trial, while four are in the pre-clinical development stage. Serum Institute of India is leading the vaccine development race in the country. SII and the Indian Council of Medical Research (ICMR) are jointly conducting phase II/III trials of Oxford’s <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword> in India. Here are the latest developments on COVID-19 vaccines in India: No major adverse side-effects reported so far in vaccine trial at PGI Chandigarh The late phase trials of the Oxford-AstraZeneca vaccine, known as Covishield in India, are well underway at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, the institute said on Thursday The officials at the premier institute told IANS that no adverse side-effects among the volunteers have been observed so far. "Very few people developed fever or body ache post vaccine administration. It is expected and very normal after the vaccine dose is given. Nothing to get alarmed about," an official informed. The institute is listed as one of the 17 trial sites for conducting the second and third phases of human clinical trials of the Coveshield vaccine. The officials added that 53 participants in the trials have already completed seven days of post vaccination period without developing any major side-effects. They also informed that the institute has screened 97 volunteers till date and 65 of them have already been administered the first dose of the vaccine. Indian-origin researchers use bovine adenovirus to develop coronavirus vaccine Oct 8 (IANS) A team of Indian-origin researchers in the US is working to develop a unique Covid-19 vaccine that uses a bovine adenovirus that will protect all segments of the population, especially older adults. Bovine Adenovirus, also known as BAdV, is a member of the Adenoviridae family that causes disease in cattle. "Adenoviral vectors have emerged as a promising gene-delivery platform for a variety of therapeutic and vaccine purposes during the last two decades," said study author Suresh Kuchipudi from Penn State University in the US Moderna to apply for real-time reviews for its COVID-19 virus in Europe: Reuters US pharma giant Moderna said it will apply real-time reviews in Europe. It is in talks with European countries and is also planning to get approval from U.S. Food and Drug Administration. Real-time reviews will allow researchers to give feedbacks without waiting for studies to conclude, reported <a href="https://www.reuters.com/article/us-health-coronavirus-moderna/moderna-to-apply-for-eus-rolling-approval-for-covid-19-vaccine-idUSKBN26T21A" data-type="tilCustomLink">Reuters. </a> Government to map out cold chain storage facilities for COVID-19 vaccine delivery With the likelihood of a vaccine against coronavirus being available within months, the government has begun a massive exercise to map out cold chain storage facilities to ensure the vaccine is delivered quickly across the country. A national expert group is talking to public and private sector entities in the pharmaceutical sector, food processing industry and agro businesses as well as food delivery start-ups such as Swiggy and Zomato to identify cold storages or fridges at the taluka level that can stock and distribute the vaccine, sources with direct knowledge of the discussions said. India's drug controller reject Dr. Reddy's proposal to test Russian coronavirus vaccine India's drug controller has rejected Dr. Reddy's proposal to test Russian coronavirus vaccine in a large study stating early-age study to be small. An expert panel of Central Drugs Standard Control Organisation has asked Dr Reddy's to first conduct small study. Previously, CDSCO asked Dr Reddy's Laboratories to submit a revised protocol for conducting both phase 2 and phase 3 human clinical trials for the Russian vaccine against COVID-19, Sputnik V, in India, sources said Monday.The Hyderabad-based pharmaceutical company had applied to the Drugs Controller General of India (DCGI) late last week, seeking permission to conduct phase-3 human clinical trials of the Russian vaccine. India plans procure 400-500 million doses of vaccine for 25 crore people by 2021 Union Health Minister Harsh Vardhan said on Sunday that the Centre is working on plans to procure 400-500 million doses of Covid-19 vaccine, which will be administered to up to 25 crore people by July 2021. He also indicated that the frontline workers and those having underlying health conditions are in the top priority list of the government for vaccine administration, saying that his ministry is currently preparing a format in which states will submit lists of priority population groups to receive the vaccine, especially health workers engaged in the management of Covid-19. In India, three potential COVID-19 vaccines are under advanced clinical trials According to <a href="https://vaccine.icmr.org.in/covid-19-vaccine">ICMR</a>, there are three potential COVID-19 vaccines under human trials — Bharat Biotech’s COVAXIN, Oxford’s Covishield, and Zydus Cadila’s ZyCoV-D. Serum Institute of India has already begun phase III trials of Oxford’s vaccine candidate at 17 sites across the country. Whereas, both Bharat Biotech and Zydus Cadila are conducting <a href="https://health.economictimes.indiatimes.com/news/industry/human-clinical-trials-for-covid-19-vaccine-initiated-in-india-icmr/76969682">phase I/II human</a> trials right now. India likely to approve potential COVID-19 vaccine with 50% efficiency The Indian drug regulator, Central Drugs Standard Control Organization, earlier this week, said it is planning<a href="https://www.livemint.com/news/india/india-may-approve-covid-19-vaccines-that-show-50-efficacy-in-clinical-trials-11600764175238.html"> </a>on approving the COVID-19 vaccine that can protect 50% of the participants in phase III human trials. “To ensure that a widely deployed COVID-19 vaccine is effective, the primary efficacy endpoint point estimate for a placebo-controlled efficacy trial should be at least 50%," the Central Drugs Standard Control Organization (CDSCO) The Health Ministry also launched a <a href="https://vaccine.icmr.org.in/">portal </a> on September 29 that will provide important information on vaccine development, ongoing clinical trials and progress made - both locally and globally. Previously, World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus has <a href="https://www.livemint.com/news/india/who-chief-lauds-pm-modi-for-his-commitment-in-fight-against-covid-19-pandemic-11601181436330.html">lauded </a>Prime Minister Narendra Modi's assurance that India will use its vaccine production capacity in helping nations fight COVID-19. WHO chief said that the pandemic can be defeated only by mobilising resources for common good. The Indian government is optimistic about getting a COVID-19 vaccine by the start of 2021. Moreover, the Ministry of Health and information <a href="https://www.ndtv.com/india-news/dont-agree-with-rs-80-000-crore-figure-for-covid-vaccine-distribution-centre-2302956">believe </a>they’ve sufficient funds to distribute COVID-19 vaccines in the country. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/policy/economy/news/manufacturing-in-india-improved-for-a-second-straight-month-sees-fastest-pace-of-growth-in-over-8-years/articleshow/78422225.cms">Manufacturing in India improved for a second straight month — sees fastest pace of growth in over 8 years</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/news/reliance-has-bagged-nearly-half-of-all-private-equity-investments-in-india-this-year-and-that-doesnt-include-the-10-billion-from-facebook-and-google/articleshow/78422299.cms">Reliance has bagged nearly half of all private equity investments in India this year – and that doesn’t include the $10 billion from Facebook and Google</a>

India COVID-19 vaccine updates — Oxford's potential coronavirus vaccine reports no side affect so far in vaccine trial at PGI Chandigarh

US drug maker <keyword id="44612" type="General" weightage="20" keywordseo="pfizer" source="Orion">Pfizer</keyword>'s Covid-19 vaccine is likely to get authorization for providing vaccines to children aged between 5 to 12 by October, according to Scott Gottlieb, former head of the Food and Drug Administration (FDA). Currently of the three Covid-19 vaccines used in the US, only the Pfizer-BioNTech vaccine has been granted the emergency use authorisation for children aged 12 and older. Pfizer along with Moderna and Johnson and Johnson are conducting clinical trials to evaluate the safety and efficacy of the vaccines in children under 12. Results of the Pfizer vaccine for children are expected in September. "Pfizer will be in a position to file data with the FDA at some point next month, and then submit its application to expand its emergency use authorisation for its vaccine in children 5 years and older as early as October," Gottlieb was quoted as saying in an interview on CBS News on Sunday. "The agency (FDA) will be in a position to make an authorisation, I believe, at some point, late fall, probably early winter. "And probably they're going to base their decision on what the circumstances around the country are, and what the urgency is to get a vaccine for kids," Gottlieb, who is also a member of Pfizer's board of directors, told CBC News. Pfizer has also been conducting clinical trials of its Covid-19 shot in children ages 2 and older. The results will be available in November. If the FDA authorises Pfizer's vaccine in kids between the ages of 5 and 11 in November or early December, "that, again, puts you on a timeframe that you could start rolling out these vaccinations before the end of the year", Gottlieb noted. Vaccinating younger children against Covid would be crucial as the highly contagious Delta variant is driving cases, particularly among the children. According to Gottlieb, there are roughly 300 kids being hospitalised each day with Covid-19, and infection rates among children have spiked with schools reopening. The two "best things" schools can do, Gottlieb said, is testing students twice a week and keeping them in geographic or social pods to cut down on intermingling among the full student body. Gottlieb also advocated for students to wear face masks and schools to improve ventilation, as well as vaccinated those who are currently eligible. SEE ALSO <a href="https://www.businessinsider.in/science/health/news/mukesh-ambanis-reliance-life-sciences-gets-approval-to-conduct-trials-for-its-covid-19-vaccine/articleshow/85677741.cms">Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far</a> <a href="https://www.businessinsider.in/business/auto/news/tata-motors-is-the-casualty-of-jlr-struggling-due-to-the-global-chip-shortage-and-a-lacklustre-ev-vision/articleshow/85652897.cms">Tata Motors is paying the price because Jaguar Land Rover has been slow in the EV race</a>

Pfizer's COVID-19 vaccine may be authorised for kids aged 5-12 by October, says company's board member

You Searched For "Corona Vaccine" and got 2 results

India COVID-19 vaccine updates — Oxford's potential coronavirus vaccine reports no side affect so far in vaccine trial at PGI Chandigarh

BI India Bureau

Pfizer's COVID-19 vaccine may be authorised for kids aged 5-12 by October, says company's board member

IANS

Popular Keywords

Buying Guides